Study Presentations

Five Hoosier Cancer Research Network studies, HCRN-MEL17-309, HCRN-GU20-436, HCRN-GU22-587, HCRN-LUN21-530, and HCRN-GU16-260, will be presented during ASCO.

HCRN MEL17-309 is a phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma. The authors are Suthee Rapisuwon, Richard Carvajal, George Ansstas, Katy Tsai, Leonel Hernandez-Aya, Shaheer Khan, Sunandana Chandra, J. William Harbour, Jeffrey Sosman, Adil Daud, Christina Decatur, Deniz Ozisik, Ming Tan, Michael Atkins, and Sapna Patel.

• Rapid Oral Abstract Session: Melanoma/Skin Cancers
• Abstract: https://meetings.asco.org/abstracts-presentations/233030

HCRN-GU20-436 is a phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune). The authors are Rana R. McKay, Lin Liu, Minya Pu, Arlene Araneta, Kit L. Yuen, Jennifer Gomez, Neremiah Castano, Archana Ajmera, Huihui Ye, Roberto Pili, Karie Runcie, Deaglan Joseph McHugh, Kenneth Offit, Channing Judith Paller, Naomi B. Haas, Juan Javier-Desloges, Christopher J. Kane, Tyler M Seibert, and Aditya Bagrodia.

• Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile
• Abstract: https://meetings.asco.org/abstracts-presentations/238462

HCRN GU22-587 is an advanced renal cell cancer combination immunotherapy clinical trial. The authors are Michael Serzan, Opeyemi Jegede, Robert Alter, Mehmet Bilen, David Braun, David Einstein, Naomi Haas, Daniel Herchenhorn, Jennifer King, Karie Runcie, Jeffrey Sosman, Cora Sternberg, Yuanquan (Aaron) Yang, Sabina Signoretti, Toni Choueiri, and Michael Atkins.

• Poster Session: Genitourinary Cancer—Kidney and Bladder
• Abstract: https://meetings.asco.org/abstracts-presentations/238451

HCRN LUN21-530 is a phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART). The authors are Hirva Mamdani, Seongho Kim, Ryan Gentzler, Misty Shields, Muhammad Furqan, Kristen Pizana, Qura Abid, and Shadia Jalal

• Poster Session: Lung Cancer
• Abstract: https://meetings.asco.org/abstracts-presentations/238527

HCRN GU16-260 is a phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). The authors are Jacob Zaemes, Miya Hugaboom, Valisha Shah, Naomi Haas, David McDermott, Opeyemi Jegede, Mehmet Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth Plimack, Michael Hurwitz, Catherine Wu, David Einstein, Hans Hammers, Sabina Signoretti, Destiny West, Thomas Denize, Michael Atkins, and David Braun.

• Poster Session: Genitourinary Cancer—Kidney and Bladder
• Abstract: https://meetings.asco.org/abstracts-presentations/231926

Working Group Meetings

HCRN will host in-person meetings for the Breast Cancer, Gastrointestinal, Thoracic, and  Genitourinary Clinical Trial Working Groups during ASCO 2024. For more information or to schedule time to meet with HCRN, please reach out to Randy Dillinger at rdillinger@hoosiercancer.org.

Reception

HCRN is hosting a combined reception for members of both HCRN and the Big Ten Cancer Research Consortium on Saturday, June 1 from 6:30 pm – 8:30 pm to celebrate 50 combined years of service to cancer research. This gathering will take place at voco Chicago Downtown 350 W. Wolf Point Plaza, in the LaSalle Room. For more information, please contact Debbie Schlegel at dschlegel@hoosiercancer.org.

Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants in have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis